| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9687487 | ALEXZA PHARMS | Aerosol forming device for use in inhalation therapy |
Oct, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439907 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(2 years ago) | |
| US7090830 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(2 years ago) | |
| US7585493 | ALEXZA PHARMS | Thin-film drug delivery article and method of use |
Oct, 2021
(2 years ago) | |
| US7078020 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(2 years ago) | |
| US7052679 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(2 years ago) | |
| US7601337 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(2 years ago) | |
| US8235037 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(2 years ago) | |
| US8173107 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(2 years ago) | |
| US8955512 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(2 years ago) | |
| US9440034 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(2 years ago) | |
| US6716416 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
May, 2022
(1 year, 10 months ago) | |
| US8074644 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Jul, 2022
(1 year, 8 months ago) | |
| US9370629 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(a month from now) | |
| US8991387 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(a month from now) | |
| US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(3 months from now) | |
| US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(6 months from now) | |
| US8387612 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(2 years from now) | |
Adasuve is owned by Alexza Pharms.
Adasuve contains Loxapine.
Adasuve has a total of 18 drug patents out of which 13 drug patents have expired.
Expired drug patents of Adasuve are:
- US9439907
- US7090830
- US7585493
- US7078020
- US7052679
- US7601337
- US8235037
- US8173107
- US8955512
- US9440034
- US6716416
- US8074644
- US9687487
Adasuve was authorised for market use on 21 December, 2012.
Adasuve is available in powder;inhalation dosage forms.
Adasuve can be used as adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults.
The generics of Adasuve are possible to be released after 23 October, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults
Dosage: POWDER;INHALATION
ADASUVE family patents
